Partner with Hikma.
We offer high-quality manufacturing capabilities, combining reliability and flexibility in our state-of-the-art facilities. With 30 manufacturing plants strategically located across the US, Europe, and the MENA region, we ensure that your needs are met with excellence.
Oral and nasal expertise
Newsroom
All news stories Latest news
- Hikma launches Foscarnet Sodium Injection, in the US Press Release, Product 23 September 2024 Hikma launches Foscarnet Sodium Injection, in the US
- Hikma completes Xellia acquisition Press Release, Corporate 10 September 2024 Hikma completes Xellia acquisition
- Hikma launches Clindamycin in 5% Dextrose Injection in the US Press Release, Product 03 September 2024 Hikma launches Clindamycin in 5% Dextrose Injection in the US
- Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day Press Release, Product 20 August 2024 Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
Related content